Form 4: Tonix Pharmaceuticals Director Acquires Stock Options

Carolyn E. Taylor, a director of Tonix Pharmaceuticals Holding Corp., reported the acquisition of stock options.

Summary

• On May 13, 2025, Carolyn E. Taylor, a director of Tonix Pharmaceuticals Holding Corp., acquired 10,000 stock options.
• The options have an exercise price of $20.18.
• The options vest on the earlier of the one-year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders and expire on May 13, 2035.
• The options are exercisable for 10,000 shares of common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants. It doesn't inherently indicate positive or negative performance, but rather a part of the compensation structure.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance beyond the vesting and expiration dates of the options.

Industry Context

This is a standard SEC filing related to insider transactions, common in the pharmaceutical industry where stock options are frequently used as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common component of compensation packages for directors and executives in the pharmaceutical industry.
• The vesting schedule of one year or the next annual meeting is fairly standard.
• The exercise price is set at $20.18.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates

Keywords

stock options, Form 4, director, TNXP, Tonix Pharmaceuticals, beneficial ownership